Case Report: Psoriasiform acral dermatitis successfully treated with upadacitinib: clinical evidence of JAK1-targeted therapy

Psoriasiform acral dermatitis (PAD) is an uncommon and likely underrecognized inflammatory dermatosis characterized by a psoriasiform–spongiotic phenotype with preferential involvement of distal digits and/or acral surfaces. Its nosologic status remains debated, and therapeutic responses to conventional topical measures, keratolytics, vitamin D analogues, retinoids, and immunomodulators are often limited or transient. We report two PAD cases successfully treated with the JAK1-selective inhibitor upadacitinib. The first case involved a 35-year-old man with chronic, progressively symptomatic hyperkeratotic, thickly scaling plaques affecting distal phalanges and palms, associated with marked xerosis and painful fissuring, as well as concomitant eczematous cheilitis. Baseline hematochemical tests were normal, and abdominal ultrasound plus chest x-ray were unremarkable, with no findings suggestive of occult malignancy in the differential (including Bazex syndrome). Upadacitinib 15 mg once daily led to complete clearance within two months, excellent tolerability, and no relapse after 10 months of follow-up under maintenance therapy. The second case was a 14-year-old boy with long-standing, treatment-refractory palmoplantar acral disease causing functional impairment after multiple systemic and biologic therapies; upadacitinib 15 mg once daily induced near-complete improvement within two weeks. These observations provide initial clinical evidence supporting JAK1 inhibition as a targeted option for severe, refractory PAD.

Authors

Institutions

Publication Details

Journal
Frontiers in Medicine
Published
2026-11-12
DOI
https://doi.org/10.3389/fmed.2026.1989104
Primary Topic
Psoriasis: Treatment and Pathogenesis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Case Report: Psoriasiform acral dermatitis successfully treated with upadacitinib: clinical evidence of JAK1-targeted therapy

Nicoletta Bernardini, Antonio Di Guardo, Nevena Skroza, Ilaria Proietti et al.
Frontiers in Medicine
Psoriasis: Treatment and Pathogenesis
article

Case Report: Psoriasiform acral dermatitis successfully treated with upadacitinib: clinical evidence of JAK1-targeted therapy

Nicoletta Bernardini, Antonio Di Guardo, Nevena Skroza, Ilaria Proietti, Ersilia Tolino, Umberto Gallo, Margherita Testa
article en

Abstract

Psoriasiform acral dermatitis (PAD) is an uncommon and likely underrecognized inflammatory dermatosis characterized by a psoriasiform–spongiotic phenotype with preferential involvement of distal digits and/or acral surfaces. Its nosologic status remains debated, and therapeutic responses to conventional topical measures, keratolytics, vitamin D analogues, retinoids, and immunomodulators are often limited or transient. We report two PAD cases successfully treated with the JAK1-selective inhibitor upadacitinib. The first case involved a 35-year-old man with chronic, progressively symptomatic hyperkeratotic, thickly scaling plaques affecting distal phalanges and palms, associated with marked xerosis and painful fissuring, as well as concomitant eczematous cheilitis. Baseline hematochemical tests were normal, and abdominal ultrasound plus chest x-ray were unremarkable, with no findings suggestive of occult malignancy in the differential (including Bazex syndrome). Upadacitinib 15 mg once daily led to complete clearance within two months, excellent tolerability, and no relapse after 10 months of follow-up under maintenance therapy. The second case was a 14-year-old boy with long-standing, treatment-refractory palmoplantar acral disease causing functional impairment after multiple systemic and biologic therapies; upadacitinib 15 mg once daily induced near-complete improvement within two weeks. These observations provide initial clinical evidence supporting JAK1 inhibition as a targeted option for severe, refractory PAD.

Frontiers in MedicineVol. 13
Istituto Dermopatico dell'Immacolata (IT), Sapienza University of Rome (IT)
Good health and well-being
Psoriasis: Treatment and Pathogenesis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon